Giving guarantees/indemnity/ becoming a surety for third party

Ref: NEPHROPLUS/SE/56 July 06, 2026 To To BSE Limited National Stock Exchange of India Limited P.J. Towers, Dalal Street, 5th Floor, Exchange Plaza, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 Scrip Code: 544647 Scrip Symbol: NEPHROPLUS Through: BSE Listing Centre Through: NEAPS Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir/Madam, Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we hereby inform you that this has reference to our letter bearing reference no. NEPHROPLUS/SE/34 dated May 19, 2026, whereby the Company had informed the Stock Exchanges regarding the approval granted by the Board of Directors for providing collateral/security support in favour of Citibank N.A. ("Citibank") and/or its affiliates, branches or designated lending offices, for the benefit of Nephrocare Health Services International Pte. Ltd. ("NHSI"), Singapore, an overseas wholly-owned subsidiary of the Company. In this regard, we hereby inform you that the Company has provided the aforesaid collateral/security support in favour of Citibank for the benefit of NHSI on July 06, 2026, which became effective from the same date, to enable NHSI to avail fund-based and/or non-fund-based credit facilities. The aggregate financial commitment undertaken by the Company pursuant to the aforesaid transaction amounts to USD 3,300,000 (equivalent to INR 31.22 Crore). The details as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are enclosed as Annexure I. The aforesaid information is also being made available on the Company's website at www.nephroplus.com For Nephrocare Health Services Limited (Formerly Nephrocare Health Services Private Limited) Kishore Kathri Company Secretary & Compliance Officer ICSI M.No. F9895 Encl: a/a ANNEXURE I Sr. Particulars Description 1. Name of party for which such Nephrocare Health Services International Pte. Ltd. (NHSI), guarantees or indemnity or Singapore, an overseas wholly-owned subsidiary of the surety was given Company. 2. Whether the promoter/ The transaction has been undertaken for the benefit of the said promoter group/ group overseas WOS entity. The promoter(s), promoter group and companies have any interest group companies do not have any direct or indirect interest in in this transaction? If yes, the transaction, other than to the extent of their shareholding nature of interest and details interest in the Company. The transaction has been undertaken thereof and whether the in the ordinary course of business and on an arm's length basis. same is done at “arm’s length”; 3. Brief details of such The Company has provided collateral/security support on July guarantee or indemnity or 06, 2026, in favour of Citibank N.A. ("Citibank") and/or its becoming a surety viz. brief affiliates, branches or designated lending offices, for the details of agreement entered benefit of Nephrocare Health Services International Pte. Ltd. (if any) including significant (NHSI), Singapore, an overseas wholly-owned subsidiary of the terms and conditions, Company. including amount of guarantee; The aggregate financial commitment undertaken by the Company is USD 3,300,000 (equivalent to INR 31.22 Crore). 4. Impact of such guarantees or The transaction results in a financial commitment by the indemnity or surety on listed Company of USD 3,300,000 (equivalent to INR 31.22 Crore) by entity way of providing collateral/security support in favour of Citibank for the benefit of Nephrocare Health Services International Pte. Ltd., Singapore, an overseas wholly-owned subsidiary of the Company. The transaction creates a contingent financial exposure on the Company to the extent of the aforesaid amount. Other than the aforesaid contingent financial exposure, no immediate impact on the operations, liquidity or cash flows of the Company is envisaged.